5 Biotech Earnings In Focus This Week

As most market participants already know, earnings season is now underway.

Whether one is an investor or trader, trading stocks or options, a company’s earnings release can be very profitable for some, while detrimental to others.

Although all sectors and industries are under the microscope when earnings start to flow in, one in particular to follow this earnings season is biotechnology - the industry that’s been one of the market’s top performers for the entire bull run.

The reason why the biotech industry might be watched a little more closely as of late is due to fears of a possible biotech bubble.

This upcoming week brings a handful of biotech names to keep an eye on, including a couple of the big dogs.

Speaking of, Tuesday after market close brings the release of Amgen, Inc.’s report (NASDAQ: AMGN).

Analyst’s expectations are for $2.07/share

Wednesday before market opens investors and traders will get a look at both Alexion Pharmaceuticals’ (NASDAQ: ALXN) and Amag Pharmaceuticals’ (NASDAQ: AMAG) earnings reports.

The market will be looking for $1.33/share from Alexion and $1.01/share from Amag.

On Friday morning both Biogen Idec (NASDAQ: BIIB) and Immunogen (NASDAQ: IMGN) will be releasing their reports.

Investors and analysts are wanting to see $3.91/share from Biogen and ($.25)/share from Immunogen.

Obviously, investors must conduct their own due diligence before investing in any stock, but whether one is looking to avoid or capitalize on earnings season, the biotechs should be names to watch.

The biotech stocks considered for this review were confined to those trading over $10 per share and that traded at least 500K shares a day based on a 90-day average.

Posted to The Biotech Trader on Apr 20, 2015 — 9:04 AM
Comments ({[comments.length]})
Sort By:
Loading Comments
No comments. Break the ice and be the first!
Error loading comments Click here to retry
No comments found matching this filter
Want to add a comment? Take me to the new comment box!